Evidence map›Paper›PMID 34401276›Full record

ArticleRespiratory medicine case reports2021

Improvement of constrictive bronchiolitis (bronchiolitis obliterans) after rituximab therapy in 2 patients with primary sjögren syndrome.

Kirill Lipatov, Aahd F Kubbara, Laura E Weerheim, Dante N Schiavo, Ulrich Specks, Jay H Ryu, Misbah Baqir

Open access · goldAbstract readCase Reports
In one paragraph

Article in Respiratory medicine case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Kirill LipatovDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.
Aahd F KubbaraDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.
Laura E WeerheimDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.
Dante N SchiavoDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.
Ulrich SpecksDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.
Jay H RyuDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.
Misbah BaqirDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.
Mayo Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Constrictive bronchiolitis is one of the manifestations of small-airway involvement in primary Sjögren syndrome (SS) and is associated with fixed airflow obstruction despite treatment with bronchodilators, macrolides, corticosteroids, and corticosteroid-sparing agents. Reports have shown a beneficial effect of rituximab on interstitial lung disease associated with SS, but the effect of rituximab on constrictive bronchiolitis is unknown. Herein, we present 2 cases of patients with constrictive bronchiolitis associated with SS who experienced symptomatic improvement and stabilization of pulmonary function testing (PFT) after rituximab therapy. Lung function declined in one of the patients when B cells reconstituted, with improved PFT results on re-administration of rituximab. Our case reports suggest that B cells may be involved in the pathogenesis of SS-associated constrictive bronchiolitis. Therapy targeting B cells may therefore be helpful in treating this debilitating and refractory condition. Further research is warranted.

Indexed as

Computed tomographyConstrictive bronchiolitisPrimary Sjögren syndromePulmonary function testingRituximab

Identifiers

PMID34401276
PMCPMC8348550
OpenAlexW3161794767

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.